Share on StockTwits

Smith & Nephew plc (LON:SN) was downgraded by stock analysts at Jefferies Group to a “hold” rating in a research report issued to clients and investors on Tuesday. They currently have a GBX 1,000 ($16.59) price objective on the stock. Jefferies Group’s price target indicates a potential downside of 5.03% from the stock’s previous close.

A number of other analysts have also recently weighed in on SN. Analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday. They now have a GBX 1,000 ($16.59) price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Thursday, August 28th. They now have a GBX 1,230 ($20.41) price target on the stock. Finally, analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Tuesday, August 26th. They now have a GBX 920 ($15.27) price target on the stock. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the company. Smith & Nephew plc has a consensus rating of “Hold” and a consensus target price of GBX 987.41 ($16.39).

Shares of Smith & Nephew plc (LON:SN) opened at 1045.30 on Tuesday. Smith & Nephew plc has a 1-year low of GBX 737.50 and a 1-year high of GBX 1136.00. The stock has a 50-day moving average of GBX 1038.93 and a 200-day moving average of GBX 980.2. The company’s market cap is £9.345 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.